Interferon alpha fusion protein

This page covers all Interferon alpha fusion protein drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Type I interferon receptor (IFNAR), Interferon alpha receptor (IFNAR).

Targets

Type I interferon receptor (IFNAR) · Interferon alpha receptor (IFNAR)

Phase 3 pipeline (5)

• GC3107 · Green Cross Corporation · Virology / Immunology
  GC3107 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity.
• MG1111 (Barycela inj.) · GC Biopharma Corp · Virology / Immunology
  MG1111 is a recombinant human albumin-fused interferon alpha (IFN-α) fusion protein that enhances antiviral and immunomodulatory activity.
• SIM0718 Injection · Simcere Pharmaceutical Co., Ltd · Virology / Immunology
  SIM0718 is a recombinant human serum albumin-interferon alpha fusion protein that enhances antiviral and immunomodulatory responses.
• SL1002 · Saol Therapeutics Inc · Oncology, Virology, Immunology
  SL1002 is a recombinant human serum albumin-interferon alpha fusion protein that enhances innate immune responses against viral infections and cancer.
• STSP-0601 for Injection · Staidson (Beijing) Biopharmaceuticals Co., Ltd · Virology/Immunology
  STSP-0601 is a recombinant human serum albumin-interferon alpha fusion protein that enhances antiviral and immunomodulatory responses.